FindTrial
Sign In

ERAS-007

DRUG4 trials

Sponsors

Erasca, Inc.

Conditions

Acute Myeloid LeukemiaAdvanced Non-squamous Non-small-cell Lung CancerAdvanced or Metastatic Solid TumorsMetastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma

Phase 1

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
CompletedNCT04866134
Erasca, Inc.Advanced or Metastatic Solid Tumors
Start: 2021-05-07End: 2026-07-01Updated: 2026-09-16
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
CompletedNCT04959981
Erasca, Inc.Advanced Non-squamous Non-small-cell Lung Cancer
Start: 2021-09-02End: 2023-04-27Updated: 2023-07-25
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
CompletedNCT05039177
Erasca, Inc.Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Start: 2021-09-20End: 2026-01-26Updated: 2026-03-25
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
WithdrawnNCT05279859
Erasca, Inc.Acute Myeloid Leukemia
Start: 2022-03-15End: 2025-06-01Updated: 2022-06-15

Related Papers

Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study.
Journal of Clinical Oncology2024-06-011 citations
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).
Journal of Clinical Oncology2023-06-012 citations
Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).
Journal of Clinical Oncology2023-06-011 citations
Abstract 2670: ERAS-601, a potent allosteric inhibitor of SHP2, synergistically enhances the efficacy of sotorasib/adagrasib and cetuximab in NSCLC, CRC, and HNSCC tumor models
Cancer Research2022-06-153 citations
Abstract 2672: ERAS-007 is a selective ERK1/2 inhibitor with preclinical activity across RAS/MAPK pathway-driven CRC models
Cancer Research2022-06-151 citations